Acura Pharmaceuticals, Inc.  

(Public, NASDAQ:ACUR)   Watch this stock  
Find more results for ACUR
0.500
-0.050 (-9.09%)
Jan 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.50 - 0.60
52 week 0.41 - 2.12
Open 0.52
Vol / Avg. 0.00/156,657.00
Mkt cap 23.58M
P/E     -
Div/yield     -
EPS -0.28
Shares 48.85M
Beta 1.72
Inst. own 57%
Mar 2, 2015
Q4 2014 Acura Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Nov 4, 2014
Q3 2014 Acura Pharmaceuticals Inc Earnings Call
Nov 3, 2014
Q3 2014 Acura Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -2002.76% -11301.63%
Operating margin -1824.83% -11455.28%
EBITD margin - -11143.09%
Return on average assets -56.63% -48.19%
Return on average equity -130.30% -61.03%
Employees 15 -
CDP Score - -

Address

Suite 120, 616 N. North Court
PALATINE, IL 60067
United States - Map
+1-847-7057709 (Phone)
+1-847-7055399 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed two proprietary technologies. The Company�s Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. The Company�s Impede Technology is a combination of inactive ingredients preventing the extraction of pseudoephedrine from tablets and disrupts the direct conversion of pseudoephedrine from tablets into methamphetamine. The Company has seven additional opioid products utilizing Aversion in various stages of development. The Company markets products using telemarketing, direct mail, and online and journal advertising.

Officers and directors

Robert B. Jones President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Peter A. Clemens Chief Financial Officer, Senior Vice President, Secretary
Age: 61
Bio & Compensation  - Reuters
Robert A. Seiser CPA Vice President, Corporate Controller and Treasurer
Age: 50
Bio & Compensation  - Reuters
J. Bradley Rivet Vice President - Marketing
Age: 60
Bio & Compensation  - Reuters
Albert W. Brzeczko Ph.D. Vice President -Technical Affairs
Age: 57
Bio & Compensation  - Reuters
James F. Emigh Vice President - Corporate Development
Age: 58
Bio & Compensation  - Reuters
George K. Ross Independent Director
Age: 72
Bio & Compensation  - Reuters
William G. Skelly Independent Director
Age: 63
Bio & Compensation  - Reuters
Immanuel Thangaraj Independent Director
Bio & Compensation  - Reuters
Bruce F. Wesson Independent Director
Age: 71
Bio & Compensation  - Reuters